Login
- Title:
Pancreatic cancer: a review of recent advances.
- Document type:
- Journal Article; Review; Review
- Author(s):
- Eckel, F; Schneider, G; Schmid, RM
- Abstract:
- Pancreatic cancer is one of the most common causes of cancer-related death. Despite the advances of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. Overall, the 5-year survival rate is < 5% and only approximately 20% of the 10% of patients with resectable disease survive 5 years. Recently, the European Study Group for Pancreatic Cancer 1 trial demonstrated substantially increased survival from adjuvant chemotherapy with 5-fluorouracil-folinic acid and preliminary data showed prolonged disease-free survival from adjuvant gemcitabine. Current palliative therapeutic approaches mostly focused on evaluating chemotherapy regimens in which gemcitabine is combined with a second cytotoxic agent. Recently, large randomised trials of combinations of gemcitabine with either capecitabine or with erlotinib demonstrated prolonged survival and 1-year survival rates of approximately 25%. The advance of molecular biology has led to the elucidation of molecular events that are important for pancreatic carcinogenesis and has provided a foundation for the development of novel chemotherapeutic and biological agents that appear to be promising and are likely to play a future role in the treatment of patients with advanced pancreatic cancer.
- Journal title abbreviation:
- Expert Opin Investig Drugs
- Year:
- 2006
- Journal volume:
- 15
- Journal issue:
- 11
- Pages contribution:
- 1395-410
- Language:
- eng
- Fulltext / DOI:
- doi:10.1517/13543784.15.11.1395
- Pubmed ID:
- http://view.ncbi.nlm.nih.gov/pubmed/17040199
- Print-ISSN:
- 1354-3784
- TUM Institution:
- II. Medizinische Klinik und Poliklinik (Gastroenterologie)
BibTeX